Literature DB >> 11507184

A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection.

M A Poles1, J Elliott, P Taing, P A Anton, I S Chen.   

Abstract

The gastrointestinal mucosa harbors the majority of the body's CD4(+) cells and appears to be uniquely susceptible to human immunodeficiency virus type 1 (HIV-1) infection. We undertook this study to examine the role of differences in chemokine receptor expression on infection of mucosal mononuclear cells (MMCs) and peripheral blood mononuclear cells (PBMCs) by R5- and X4-tropic HIV-1. We performed in vitro infections of MMCs and PBMCs with R5- and X4-tropic HIV-1, engineered to express murine CD24 on the infected cell's surface, allowing for quantification of HIV-infected cells and their phenotypic characterization. A greater percentage of MMCs than PBMCs are infected by both R5- and X4-tropic HIV-1. Significant differences exist in terms of chemokine receptor expression in the blood and gastrointestinal mucosa; mucosal cells are predominantly CCR5(+) CXCR4(+), while these cells make up less than 20% of the peripheral blood cells. It is this cell population that is most susceptible to infection with both R5- and X4-tropic HIV-1 in both compartments. Regardless of whether viral isolates were derived from the blood or mucosa of HIV-1-infected patients, HIV-1 p24 production was greater in MMCs than in PBMCs. Further, the chemokine receptor tropism of these patient-derived viral isolates did not differ between compartments. We conclude that, based on these findings, the gastrointestinal mucosa represents a favored target for HIV-1, in part due to its large population of CXCR4(+) CCR5(+) target cells and not to differences in the virus that it contains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11507184      PMCID: PMC115084          DOI: 10.1128/jvi.75.18.8390-8399.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue.

Authors:  P A Anton; J Elliott; M A Poles; I M McGowan; J Matud; L E Hultin; K Grovit-Ferbas; C R Mackay; J V Giorgi
Journal:  AIDS       Date:  2000-08-18       Impact factor: 4.177

2.  Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens.

Authors:  F Pallone; S Fais; O Squarcia; L Biancone; P Pozzilli; M Boirivant
Journal:  Gut       Date:  1987-06       Impact factor: 23.059

3.  Normal human intestinal B lymphocytes. Increased activation compared with peripheral blood.

Authors:  M G Peters; H Secrist; K R Anders; G S Nash; S R Rich; R P MacDermott
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

4.  Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue.

Authors:  C H McGavin; S A Land; K L Sebire; D J Hooker; A D Gurusinghe; C J Birch
Journal:  AIDS       Date:  1996-01       Impact factor: 4.177

5.  Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells.

Authors:  A N Akbar; L Terry; A Timms; P C Beverley; G Janossy
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

6.  Selective HIV-1-induced downmodulation of CD4 and coreceptors.

Authors:  A L Chenine; Q Sattentau; M Moulard
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

7.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

8.  Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma.

Authors:  M A Poles; J Elliott; J Vingerhoets; L Michiels; A Scholliers; S Bloor; B Larder; K Hertogs; P A Anton
Journal:  J Infect Dis       Date:  2000-11-21       Impact factor: 5.226

9.  Biological characterization of paired human immunodeficiency virus type 1 isolates from blood and cerebrospinal fluid.

Authors:  F Chiodi; A Valentin; B Keys; S Schwartz; B Asjö; S Gartner; M Popovic; J Albert; V A Sundqvist; E M Fenyö
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

10.  Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation.

Authors:  M Zeitz; W C Greene; N J Peffer; S P James
Journal:  Gastroenterology       Date:  1988-03       Impact factor: 22.682

View more
  84 in total

1.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.

Authors:  Patricia Fletcher; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

3.  CCR6(-) regulatory T cells blunt the restoration of gut Th17 cells along the CCR6-CCL20 axis in treated HIV-1-infected individuals.

Authors:  C Loiseau; M Requena; M Mavigner; M Cazabat; N Carrere; B Suc; K Barange; L Alric; B Marchou; P Massip; J Izopet; P Delobel
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

4.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

5.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

6.  Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection.

Authors:  Moraima Guadalupe; Sumathi Sankaran; Michael D George; Elizabeth Reay; David Verhoeven; Barbara L Shacklett; Jason Flamm; Jacob Wegelin; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

Authors:  Michael A Poles; Shady Barsoum; Wenjie Yu; Jian Yu; Patricia Sun; Jeanine Daly; Tian He; Saurabh Mehandru; Andrew Talal; Martin Markowitz; Arlene Hurley; David Ho; Linqi Zhang
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

Review 9.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

Review 10.  Rectal microbicide development.

Authors:  Ian McGowan; Charlene Dezzutti
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.